Skip to main content

stock

RARE · Ultragenyx Pharmaceutical Inc.

What Ultragenyx Pharmaceutical Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live RARE price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on RARE.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
98,588,873 as of 2026-07-31 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-73.6%
Net
-81.7%

Returns

ROE
—
ROA
-46.4%

Health

Current ratio
1.7x
Debt/equity
—

Deep value

NCAV
-$942.00M
NCAV per share
-$9.55
Price/NCAV
Locked
NNWC
-$1.24B
NNWC per share
-$12.61
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$214.00M—Gross profit: unreported by this company.-$75.00M-$92.00M
10-Q filed 2026-08-05
2026-03-31$136.00M—Gross profit: unreported by this company.-$169.00M-$185.00M
10-Q filed 2026-05-06
2025-12-31$207.07M—Gross profit: unreported by this company.-$113.11M-$128.59M
10-K filed 2026-02-18
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-09-30$159.93M—Gross profit: unreported by this company.-$170.89M-$180.41M
10-Q filed 2025-11-05
2025-06-30$167.00M—Gross profit: unreported by this company.-$108.00M-$115.00M
10-Q filed 2026-08-05
2025-03-31$139.00M—Gross profit: unreported by this company.-$143.00M-$151.00M
10-Q filed 2026-05-06
2024-12-31$164.65M—Gross profit: unreported by this company.-$122.31M-$133.20M
10-K filed 2026-02-18
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2024-09-30$139.49M—Gross profit: unreported by this company.-$131.99M-$133.52M
10-Q filed 2025-11-05
Assets
$1.26B
Equity
-$291.00M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$673.00M-$535.00M-$575.00M-$472.00M
2024-12-31$560.00M-$536.00M-$569.00M-$421.00M
2023-12-31$434.00M-$569.00M-$607.00M-$519.00M
2022-12-31$363.33M-$648.92M-$707.42M-$496.59M
2021-12-31$351.41M-$381.74M-$454.02M-$411.79M
2020-12-31$271.03M-$330.12M-$186.57M-$176.13M
2019-12-31$103.71M-$424.17M-$402.73M-$370.21M
2018-12-31$51.49M-$371.37M-$197.61M-$294.64M
2017-12-31$2.61M-$328.94M-$302.14M-$256.64M
2016-12-31$133,000-$248.01M-$245.87M-$171.16M

Company filings

events

  • Other event

    Other event
    Sep 178-K
  • Other event

    Other event
    Sep 28-K
  • Other event

    Other event
    Aug 198-K
  • Other event

    Other event
    Aug 118-K
  • Results

    Results
    Aug 48-K
  • Executive or director change, Shareholder vote results

    Executive or director changeShareholder vote results
    May 188-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    Sale$17,410

    Sep 15, 6:57 PM ET

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    Sale$2,252

    Sep 8, 12:29 PM ET

  • Parschauer Karah Herdman

    EVP and Chief Legal Officer

    Sale$47,348

    Aug 4, 3:15 PM ET

  • Horn Howard

    Chief Financial Officer

    Sale$117,024

    Aug 4, 3:13 PM ET

All insider trades for RARE

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named RARE, and the market events around them.

Sign in to see this

Board

The RARE board could not be loaded.

Retry the RARE board

nakagai

Signals on RARE come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the RARE board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Ultragenyx Pharmaceutical Inc. (RARE): SEC filings, financials and insider trades · Nakagai